Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
GlobalData on MSN13d
GSK’s Phase I/II herpes simplex vaccine trial misses primary endpointGSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine ...
Future Microbiol. 2010;5(1):15-22. The ocular and genital mucosa are key players in regulation of herpes simplex virus (HSV) susceptibility and recurrent disease. Prophylactic and therapeutic ...
The newly introduced Novaplex™ MPXV/OPXV plus Assay (RUO) is designed to detect 3 targets causing mpox disease: non-variola ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A safety update for abrocitinib has shown the drug to be ...
has been demonstrated preclinically to be more effective in the destruction of the Herpes Simplex Virus 1 ("HSV-1") than the currently approved standard of care drug, Acyclovir. Acyclovir is an ...
Background: Herpes zoster is more prevalent among the older adult due to the age-related immune decline, leading to significant pain and complications. Although vaccination effectively prevents viral ...
As herpes simplex is most often acquired during delivery rather than during gestation, it is more preventable and treatable compared with CMV or rubella. Like the varicella-zoster virus ...
Working with herpes simplex virus (HSV), a new study led by Harvard Medical School researchers sheds light on one of the ways in which the virus becomes resistant to treatment, a problem that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback